Tectonic therapeutic announces second quarter 2024 financial results and recent business highlights

Tx45 advances into phase 2 clinical trial for patients with group 2 ph-hfpef with first site activated and screening open in august 2024 received u.s. investigational new drug (ind) clearance for lead program, tx45 in july 2024 completed reverse merger with avrobio in june 2024, including concurrent private placement of $130.7 million cash and cash equivalents were $185.1 million as of june 30, 2024, prior to the payment of accrued transaction and related expenses of approximately $14.4 million, are expected to provide cash runway into mid-2027 watertown, mass., aug. 14, 2024 (globe newswire) -- tectonic therapeutic, inc. (nasdaq: tecx) (“tectonic”, or “the company”), a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of g-protein coupled receptors (gpcrs), today announced its financial results for the second quarter ending june 30, 2024, and provided an overview of recent business highlights.
TECX Ratings Summary
TECX Quant Ranking